Human Anti-PDCD1 Recombinant Antibody (clone hPD-1.08A) (CAT#: HPAB-661-FY)

Figure 1 Shows the results of experiments demonstrating that antibodies against human PD-1 bind to PD-1.

A graph shows dose dependent binding of anti-PD-1 antibodies to purified PD-1/Fc in a protein ELISA.

Figure 2 Shows the results of experiments demonstrating that antibodies against human PD-1 bind to PD-1.

A graph shows dose dependent binding of anti PD-1 antibodies to PD-1 expressed on the surface of CHO cells transfected with hPD-1 in a CELISA.

Figure 3 Shows results of FMAT experiments demonstrating that the antibodies against PD-1 compete for binding of PD-L1 and PD-L2 to CHO cells transfected with human PD-1.

A graph shows dose dependent inhibition of binding of PD-L1 by hPD-1.08A and hPD-1.09A and to a lesser extent by J116.

Figure 4 Shows results of FMAT experiments demonstrating that the antibodies against PD-1 compete for binding of PD-L1 and PD-L2 to CHO cells transfected with human PD-1.

A graph shows dose dependent inhibition of PD-L2.

Figure 5 A bar graph shows the results of SEB-stimulated IL-2 production by healthy donor blood cells is enhanced in the presence of anti-PD-1, anti PD-L1 or anti-CTLA-4 antibodies.

Figure 6 Shows results of experiments demonstrating that anti-PD-1 antibodies promote T cell proliferation and cytokine secretion (IL-2 and IFNγ) when stimulated with the recall antigen tetanus toxoid.

Figure 7 A graph depicts the kassoc and kdissoc rates for anti-PD-1 antibodies as measured by bio-light interferometry. Diagonal lines indicate theoretical calculated KD values.